All In Biotech

NDA 020612 · Teikoku Pharma USA

Lidoderm

Lidocaine · Topical · Amide Local Anesthetic; Antiarrhythmic

Orphan

Last checked: Nov 20, 2026Latest source record: Nov 2, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Mar 19, 1999

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,569

373 Phase 3, 196 recruiting

FAERS reports

57,026

40,998 serious, 5,778 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 29, 2026.

INDICATION AND USAGE LIDOCAINE PATCH 5% is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin .

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LIDODERM · LIDOCAINE 5% · PATCH, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lidocaine" as an intervention, any sponsor and status, largest first.

All 2,569 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,078
  • pain3,849
  • nausea3,652
  • fatigue3,632
  • headache3,220
  • off label use2,920
  • dyspnoea2,617
  • diarrhoea2,388
  • pneumonia2,356
  • vomiting2,220
  • fall2,149
  • dizziness2,087

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004307
2005302
2006422
2007435
2008539
2009652
2010886
20111,491
20121,671
20131,140
20141,548
20152,564
20164,104
20173,075
20183,825
20194,650
20205,794
20214,030
20223,737
20234,121
20244,117
20254,291
20263,321

Recalls

1 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lidoderm (Lidocaine)

2024 spending

$642K

Beneficiaries

238

583 claims

Per beneficiary

$2,700

$23.51 per unit

View as table
YearSpending
2020$12,579,353
2021$12,010,513
2022$12,289,964
2023$2,645,970
2024$642,496

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,282 on PubMed

Sponsor: Teikoku Pharma USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.